Kedrion supports initiatives for World Haemophilia Day. Partner in a project for export of blood-derived products from national plasma for humanitarian purposes
Kedrion confirms its support of the World Haemophilia Day, an initiative that is now in its 9th year in Italy and is usually celebrated on 17th April, aimed to raise awareness of haemophilia and similar conditions. The slogan chosen by the World Federation of Haemophilia (WFH) for 2013, again, is “Close the Gap”, a catchphrase
Agreement with Entegrion for the development and marketing of Resusix™, a virus inactivated spray-dried plasma
Kedrion Melville Inc., a US-based company owned by Kedrion, entered into an agreement with the US-based company Entegrion Inc. for the development and marketing of Resusix™, a virus inactivated spray-dried plasma, treated with solvent-detergent, to be used as a replacement of frozen fresh plasma. The Phase-I clinical trials that have recently been authorised by the
The Jeffrey Modell Foundation visits Kedrion
Today, Vicki and Fred Modell, founders of the Jeffrey Modell Foundation, met Kedrion’s management in the company’s headquarters in Castelvecchio Pascoli. JMF is an international non-profit organisation founded in 1987 in memory of their son Jeffrey who died at the age of 15 from complications of Primary Immunodeficiency (PI), and works to help patients affected
Kedrion supports Italy’s first Jeffrey Modell Paediatric Immunology Centre
With a three-year donation, Kedrion supported the creation of the first Jeffrey Modell Paediatric Immunology Centre in Italy. As a matter of fact, from now on the Paediatric Immunology Centre of Meyer University Hospital in Florence will be part of the Jeffrey Modell Centres network for the diagnosis, treatment and research of Primitive Immune Deficiencies
First official visit of the Regional Health Councillor for Tuscany, Luigi Marroni
Yesterday, the Regional Health Councillor for Tuscany, Luigi Marroni visited Kedrion, an Italian leading biopharmaceutical company and also one of the top worldwide companies in the development, production and distribution of plasma-derived products. The Councillor, who was on his first official visit, met Paolo Marcucci, Kedrion’s President and CEO. Hon. Marroni visited Kedrion Group’s main
Kedrion reinforces its presence in the United States. Agreement with US-bades OCD for the acquisition of one of the company’s branches
Kedrion reinforces its presence in the United States. The company, based in Castelvecchio Pascoli (Lucca), acquired from Ortho-Clinical Diagnostics, Inc. (OCD) the branch specialising in the production of human anti-D immunoglobulin, an effective product for the prevention of the “haemolytic disease of the newborn” (HDN), a condition that occurs in Rh-positive foetuses and new-born babies
Kedrion supports the congress “Hot Topics in Liver Transplant: new viruses and Hepatitis B”
The III edition of the congress "Hepatitis B, surgery and liver transplant – Hot Topics in Liver Transplant: new viruses and Hepatitis B”, supported by Kedrion, takes place on 8th and 9th June. The event is being held at the Renaissance Tuscany Il Ciocco Resort and Spa with over 100 Italian transplantologists and hepatologists attending,
Italian Strategic Fund invests in Kedrion
Fondo Strategico Italiano (FSI), the Italian Strategic Fund, has become a joint owner of Kedrion with an overall financial contribution of 150 million euros (75 million euros in capital increase and 75 million euros in a convertible or reimbursable line of credit). The company’s ownership will be divided as follows: 48.8 per cent to the
Kedrion supports the World Haemophilia Day
Kedrion confirms its commitment to improving access to treatment and protecting the therapeutic standards of people suffering from haemophilia and other haemorrhagic conditions. The company is actually one of the supporters of the initiatives implemented in Rome by FedEmo (Federation of haemophilic patients’ associations) and in Milan by Fondazione Paracelso to celebrate the eighth World
Kedrion CEO assumes board helm of Plasma Protein Therapeutics Association
At the yearly PPTA meeting in Brussels, Paolo Marcucci has been elected as new chairman of the Global Board of Directors of the Plasma Protein Therapeutics Association. Paolo Marcucci has served on the PPTA Global Board of Directors since 2008. “It will be a great honor and privilege to serve as the new chairman of